[1]陈 旸,曾 川,张献全.肝细胞肝癌的靶向及免疫治疗研究现状与进展[J].医学信息,2019,(03):45-48.[doi:10.3969/j.issn.1006-1959.2019.03.015]
 CHEN Yang,ZENG Chuan,ZHANG Xian-quan.Current Status and Progress of Research on Hepatocellular Carcinoma Targeting and Immunotherapy[J].Medical Information,2019,(03):45-48.[doi:10.3969/j.issn.1006-1959.2019.03.015]
点击复制

肝细胞肝癌的靶向及免疫治疗研究现状与进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年03期
页码:
45-48
栏目:
综述
出版日期:
2019-02-01

文章信息/Info

Title:
Current Status and Progress of Research on Hepatocellular Carcinoma Targeting and Immunotherapy
文章编号:
1006-1959(2019)03-0045-04
作者:
陈 旸曾 川张献全
(重庆医科大学附属第二医院肿瘤科,重庆 400000)
Author(s):
CHEN YangZENG ChuanZHANG Xian-quan
(Department of Oncology,The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400000,China)
关键词:
肝细胞肝癌靶向治疗免疫治疗
Keywords:
Hepatocellular carcinomaTargeted therapyImmunotherapy
分类号:
R735.7
DOI:
10.3969/j.issn.1006-1959.2019.03.015
文献标志码:
A
摘要:
近年来,肝细胞肝癌的发病率呈逐渐上升趋势,已成为世界范围关注的健康问题,且患者常常初诊已为晚期,失去手术治疗的机会,预后较差。目前靶向治疗和免疫治疗是继传统放化疗之后的又一里程碑式进展,其在晚期肝癌治疗中应用广泛,多种药物已被证实有明确的生存获益及良好的安全性,本文主要就肝细胞肝癌在靶向治疗和免疫治疗方面的研究情况进行综述。
Abstract:
In recent years, the incidence of hepatocellular carcinoma has gradually increased, and it has become a worldwide health concern, and patients often have a late diagnosis, an opportunity to lose surgery, and a poor prognosis. At present, targeted therapy and immunotherapy are another milestone after traditional chemoradiotherapy. They are widely used in the treatment of advanced liver cancer. Many drugs have been proven to have clear survival benefits and good safety. Hepatocellular carcinoma is reviewed in the field of targeted therapy and immunotherapy.

参考文献/References:


[1]Kew MC.Hepatocellular carcinoma: epidemiology and risk factors[J].J Hepatocell Carcinoma,2014(1):115-125.
[2]Saad NS,Floyd K,Ahmed AA,et al.The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities[J].PLoS One,2016,11(4):e0153694.
[3]Keating GM.Sorafenib: A Review in Hepatocellular Carcinoma[J].Target Oncol,2017,12(2):243-253.
[4]Ye SL,Yang J,Bie P,et al.Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study[J].BMC Cancer,2018,18(1):247.
[5]Jackson R,Psarelli EE,Berhane S,et al.Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials[J].J Clin Oncol,2017,35(6):622-628.
[6]Bruix J,Raoul JL,Sherman M,et al.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial[J].J Hepatol,2012,57(4):821-829.
[7]Weinmann A,Alt Y,Koch S,et al.Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma[J].BMC Cancer,2015(15):210.
[8]Pinyol R,Montal R,Bassaganyas L,et al.Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial[J].Gut,2018.
[9]Gao L,Wang X,Tang Y,et al.FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib[J].J Exp Clin Cancer Res,2017,36(1):8.
[10]Rimassa L,Assenat E,Peck-Radosavljevic M,et al.Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study[J].Lancet Oncol,2018,19(5):682-693.
[11]Santoro A,Rimassa L,Borbath I,et al.Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study[J].Lancet Oncol,2013,14(1):55-63.
[12]Bruix J,Tak WY,Gasbarrini A,et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study[J].Eur J Cancer,2013,49(16):3412-3419.
[13]Bruix J,Qin S,Merle P,et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet,2017,389(10064):56-66.
[14]Kudo M,Finn RS,Qin S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J].Lancet,2018,391(10126):1163-1173.
[15]Abou-Alfa GK,Meyer T,Cheng AL,et al.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J].N Engl J Med,2018,379(1):54-63.
[16]Chau I,Park JO,Ryoo BY,et al.Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study[J].Br J Cancer,2018,119(1):19-26.
[17]Chen DS,Mellman I.Oncology meets immunology: the cancer-immunity cycle[J].Immunity,2013,39(1):1-10.
[18]Sangro B,Gomez-Martin C,de la Mata M,et al.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J].J Hepatol,2013,59(1):81-88.
[19]Waidmann O.Recent developments with immunotherapy for hepatocellular carcinoma[J].Expert Opin Biol Ther,2018,18(8):905-910.
[20]Massard C,Gordon MS,Sharma S,et al.Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer[J].J Clin Oncol,2016,34(26):3119-3125.
[21]Finkelmeier F,Waidmann O,Trojan J.Nivolumab for the treatment of hepatocellular carcinoma[J].Expert Rev Anticancer Ther,2018,18(12):1169-1175.
[22]Kudo M,Finn RS,Qin S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J].Lancet, 2018,391(10126):1163-1173.
[23]Abou-Alfa GK,Qin S,Ryoo BY,et al.Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma[J].Ann Oncol,2018,29(6):1402-1408.
[24]Ikeda M,Kobayashi M,Tahara M,et al.Optimal management of patients with hepatocellular carcinoma treated with lenvatinib[J].Expert Opin Drug Saf,2018,17(11):1095-1105.
[25]Michot JM,Bigenwald C,Champiat S,et al.Immune-related adverse events with immune checkpoint blockade: a comprehensive review[J].Eur J Cancer,2016(54):139-148.
[26]Gao J,Shi LZ,Zhao H,et al.Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy[J].Cell,2016,167(2):397-404.
[27]史业辉,佟仲生.肿瘤免疫检查点抑制剂耐药机制及逆转耐药的相关治疗进展[J].中国肿瘤临床,2018,45(15):812-815.
[28]Cabibi D,Bisanti A,Lanza D,et al.Glypican-3 and Hep Par-1 are Useful Biomarkers in the Cytologic Assessment of Ascites[J].Appl Immunohistochem Mol Morphol,2018.
[29]Sawada Y,Yoshikawa T,Ofuji K,et al.Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients[J].Oncoimmunology,2016,5(5):e1129483.

相似文献/References:

[1]袁国辉,戴 超,吴兆平,等.CyclinA2基因多态性与肝细胞肝癌易感性的关系[J].医学信息,2018,(22):77.[doi:10.3969/j.issn.1006-1959.2018.22.021]
 YUAN Guo-hui,DAI Chao,WU Zhao-ping,et al.Relationship between Polymorphism of CyclinA2 Gene and Susceptibility to Hepatocellular Carcinoma[J].Medical Information,2018,(03):77.[doi:10.3969/j.issn.1006-1959.2018.22.021]
[2]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
 ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Medical Information,2018,(03):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[3]牛 悦,白建平,卢建跃.HER-2阳性胃癌的研究进展[J].医学信息,2019,(01):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
 NIU Yue,BAI Jian-ping,LU Jian-yue.Progress in Research of HER-2 Positive Gastric Cancer[J].Medical Information,2019,(03):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
[4]孙 峰,鲍扬漪,朱 婷,等.晚期结直肠癌抗血管生成靶向治疗研究进展[J].医学信息,2019,(17):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]
 SUN Feng,BAO Yang-yi,ZHU Ting,et al.Advances in Anti-angiogenesis Targeted Therapy for Advanced Colorectal Cancer[J].Medical Information,2019,(03):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]

更新日期/Last Update: 2019-02-25